GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » Price-to-Owner-Earnings

Vifor Pharma AG (LTS:0RPD) Price-to-Owner-Earnings : 36.15 (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG Price-to-Owner-Earnings?

As of today (2024-04-27), Vifor Pharma AG's share price is CHF165.55. Vifor Pharma AG's Owner Earnings per Share (TTM) ended in Dec. 2021 was CHF4.58. It's Price-to-Owner-Earnings for today is 36.15.


The historical rank and industry rank for Vifor Pharma AG's Price-to-Owner-Earnings or its related term are showing as below:

LTS:0RPD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.29   Med: 34.59   Max: 382.58
Current: 37.41

During the past 13 years, the highest Price-to-Owner-Earnings of Vifor Pharma AG was 382.58. The lowest was 7.29. And the median was 34.59.


LTS:0RPD's Price-to-Owner-Earnings is not ranked
in the Drug Manufacturers industry.
Industry Median: 27.58 vs LTS:0RPD: 37.41

As of today (2024-04-27), Vifor Pharma AG's share price is CHF165.55. Vifor Pharma AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was CHF2.22. Therefore, Vifor Pharma AG's PE Ratio (TTM) for today is 74.57.

As of today (2024-04-27), Vifor Pharma AG's share price is CHF165.55. Vifor Pharma AG's EPS without NRI for the trailing twelve months (TTM) ended in was CHF2.25. Therefore, Vifor Pharma AG's PE Ratio without NRI for today is 73.58.

During the past 13 years, Vifor Pharma AG's highest PE Ratio without NRI was 226.19. The lowest was 27.09. And the median was 62.86.


Vifor Pharma AG Price-to-Owner-Earnings Historical Data

The historical data trend for Vifor Pharma AG's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG Price-to-Owner-Earnings Chart

Vifor Pharma AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.13 107.00 46.51 25.90 35.61

Vifor Pharma AG Semi-Annual Data
Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.51 - 25.90 - 35.61

Competitive Comparison of Vifor Pharma AG's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vifor Pharma AG's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's Price-to-Owner-Earnings falls into.



Vifor Pharma AG Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Vifor Pharma AG's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=165.55/4.58
=36.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vifor Pharma AG  (LTS:0RPD) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Vifor Pharma AG Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Vifor Pharma AG (LTS:0RPD) Business Description

Traded in Other Exchanges
N/A
Address
Rechenstrasse 37, Saint Gallen, CHE, 9014
Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (LTS:0RPD) Headlines

No Headlines